Proteomic disease prediction models generalize across biobanks

In a preprint analyzing human data across three major cohorts, researchers tested how well blood proteomic disease risk models transfer across populations. The team trained prediction models for 15 diseases using Olink proteomics from 53,026 UK Biobank participants. Across the UK Biobank, the models reached a mean AUC of 0.74 (range 0.56 to 0.89), outperforming clinical factors alone by a mean Delta AUC of 0.03. Simple L2 models performed as well as complex transformer architectures. The researchers then evaluated the models in two external cohorts: FinnGen (n=5,865) and All of Us (n=7,405). Across biobanks, 10 of 14 prevalent models and 13 of 15 incident five-year disease models showed no significant drop in performance. Differences in phenotyping quality across cohorts were identified as the primary drivers of performance variation.